Data from Pharmawand - Curated by EPG Health - Date added 17 May 2017
Twenty four month data from the BIOSOLVE-II study reveal the long-term safety, efficacy and stability of Biotronik’s Magmaris resorbable magnesium scaffold. Presented during a late-breaking trial session at EuroPCR 2017, the findings demonstrated the continued safety and efficacy of Magmaris at two years, serving as the first results since 95% resorption of the magnesium backbone. The presentation also revealed high procedure success at six months in the BIOSOLVE-III trial.
Findings from both studies are being published concurrently in EuroIntervention. Dr. Haude also presented the pooled six-month data of the BIOSOLVE-II and BIOSOLVE-III studies. The combined results demonstrated consistent and low target lesion failure at 3.3% and no incidence of definite or probable scaffold thrombosis, further confirming the safety and efficacy of Magmaris. Clinical follow-up for BIOSOLVE-III will continue for up to three years.
See-"Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III"- Published on 16 May 2017( ahead of print) -Michael Haude, MD, PhD et.,al. ; on behalf of the BIOSOLVE-II andpBIOSOLVE-III investigators.